osteoporosis

(redirected from Postmenopausal osteoporosis)
Also found in: Thesaurus, Medical, Acronyms, Encyclopedia.

os·te·o·po·ro·sis

 (ŏs′tē-ō-pə-rō′sĭs)
n. pl. os·te·o·po·ro·ses (-sēz)
A disease characterized by a decrease in bone mass and density, occurring especially in postmenopausal women, resulting in a predisposition to fractures.

[New Latin : osteo- + Greek poros, passage, pore; see pore2 + -osis.]

os′te·o·po·rot′ic (-rŏt′ĭk) adj.

osteoporosis

(ˌɒstɪəʊpɔːˈrəʊsɪs)
n
(Pathology) porosity and brittleness of the bones due to loss of calcium from the bone matrix
[C19: from osteo- + pore2 + -osis]
ˌosteopoˈrotic adj

os•te•o•po•ro•sis

(ˌɒs ti oʊ pəˈroʊ sɪs)

n.
a disorder in which the bones become increasingly porous, brittle, and subject to fracture, owing to loss of calcium and other mineral components.
[1840–50; osteo- + Greek pór(os) passage, pore2 + -osis]
os`te•o•po•rot′ic (-ˈrɒt ɪk) adj.

os·te·o·po·ro·sis

(ŏs′tē-ō-pə-rō′sĭs)
A condition in which the bones become porous and weak from loss of minerals, especially calcium.

osteoporosis

the rarefaction of bone, resulting in abnormally porous and weak bony tissue.
See also: Body, Human, Bones

osteoporosis

A group of diseases in which the resorption of bone outpaces the deposit of bone. Bones become lighter and more porous, making them susceptible to fracture.
ThesaurusAntonymsRelated WordsSynonymsLegend:
Noun1.osteoporosis - abnormal loss of bony tissue resulting in fragile porous bones attributable to a lack of calcium; most common in postmenopausal women
pathology - any deviation from a healthy or normal condition
dowager's hump - abnormal spinal curvature that results when osteoporosis causes the spine to collapse; seen most often in elderly women
Translations
osteoporóza
luukatoosteoporoosi
csontritkulás

osteoporosis

[ˌɒstɪəʊpɔːˈrəʊsɪs] Nosteoporosis f inv

osteoporosis

[ˌɒstiəʊpəˈrəʊsɪs] nostéoporose f

os·te·o·po·ro·sis

n. osteoporosis, pérdida en la densidad del hueso.

osteoporosis

n osteoporosis f
References in periodicals archive ?
TBRIA demonstrated positive safety and efficacy as a treatment for postmenopausal osteoporosis in the global, randomized, double-blind ORACAL trial.
The reduction of estrogen levels at menopause is one of the strongest risk factors for developing postmenopausal osteoporosis (Fraser et al.
Ibandronate is approved for the treatment of postmenopausal osteoporosis.
Montserrat Otero, a PhD holder in Physical Activity and Sports Sciences of the UPV/EHU-University of the Basque Country studied 68 women with postmenopausal osteoporosis of the age group 50 - 72, of whom 34 were randomly assigned to the Exercise Group and 34 to the Control Group.
GlobalData, the industry analysis specialist, has released its new report, Postmenopausal Osteoporosis Therapeutics - Pipeline Assessment and Market Forecasts to 2017.
Estrogen is approved for the prevention, but not for the treatment of postmenopausal osteoporosis.
Results from the pivotal three-year Phase 3 Fracture REduction Evaluation of Denosumab in Osteoporosis every six Months (FREEDOM) study in 7,808 women with postmenopausal osteoporosis showed that women receiving a subcutaneous injection of Prolia every six months experienced a 68 percent reduction in the relative risk of suffering a new vertebral (spine) fracture compared to those receiving placebo as well as a 40 percent reduction in the relative risk of suffering a hip fracture and a 20 percent reduction in the relative risk of suffering a nonvertebral fracture at 36 months.
Among women who did not breastfeed, there was little difference in the risk of postmenopausal osteoporosis if the first pregnancy occurred at or after age 22 or 27 years, Dr.
There remains a need for additional alternatives to treat postmenopausal osteoporosis, and there are no currently approved treatments for bone loss due to hormone ablation therapy," said Roger M.
AclastaA Approved in Jordan as the first once-yearly treatment for women with postmenopausal osteoporosis
Minneapolis, has launched new Fortical(R) calcitonin-salmon (rDNA origin) Nasal Spray, an effective treatment option for postmenopausal osteoporosis in women greater than 5 years postmenopause with low bone mass relative to healthy premenopausal women.
Key Words: bisphosphonates, glucocorticoid-induced osteoporosis, osteoporosis, postmenopausal osteoporosis, vertebral fracture

Full browser ?